Xianghua Huang1, Wencui Chen2, Guisheng Ren2, Liang Zhao2, Jinzhou Guo2, Dehua Gong2, Caihong Zeng2, Weixin Hu2, Zhihong Liu2. 1. National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China hxhszb@163.com. 2. National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
Abstract
BACKGROUND AND OBJECTIVES: Our study evaluated the efficiency and safety of autologous hematopoietic stem cell transplantation treatment for patients with refractory lupus nephritis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: From July 2011 to January 2015, a total of 22 patients with refractory lupus nephritis were enrolled in this study. Peripheral blood stem cells were mobilized with cyclophosphamide and granulocyte colony stimulating factor and reinfused after treatment with cyclophosphamide and antithymocyte globulin. The primary end point was the rate of remission, and secondary end points included the survival and relapse rates, changes in proteinuria, kidney function, and serology immunologic test. All complications were recorded for safety assessment. RESULTS: Twenty-two patients were enrolled and underwent stem cell mobilization. There were nine men and 13 women, with a median lupus nephritis duration of 46 (33-71) months. The mean number of CD34+ cells was (7.3±3.8)×106/kg. All patients had successful engraftment, and the median times of granulocyte and platelet engraftment were 8 (7-9) and 9 (6-10) days, respectively. The major complications of stem cell transplantation were fever and gastrointestinal tract symptoms. The treatment-related mortality was 5% (one of 22). After a median follow-up of 72 (60-80) months, 18 (82%) patients achieved completed remission, one (5%) patient achieved partial remission, and one patient had no response and received peritoneal dialysis at 12 months after transplantation. The 5-year overall survival and disease-free survival rates were 91% and 53%, respectively. Six patients experienced relapse during the follow-up, and the relapse rate was 27%. CONCLUSIONS: Autologous hematopoietic stem cell transplant could be used as a treatment option for refractory lupus nephritis, because it was relatively safe and associated with good outcomes.
BACKGROUND AND OBJECTIVES: Our study evaluated the efficiency and safety of autologous hematopoietic stem cell transplantation treatment for patients with refractory lupus nephritis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: From July 2011 to January 2015, a total of 22 patients with refractory lupus nephritis were enrolled in this study. Peripheral blood stem cells were mobilized with cyclophosphamide and granulocyte colony stimulating factor and reinfused after treatment with cyclophosphamide and antithymocyte globulin. The primary end point was the rate of remission, and secondary end points included the survival and relapse rates, changes in proteinuria, kidney function, and serology immunologic test. All complications were recorded for safety assessment. RESULTS: Twenty-two patients were enrolled and underwent stem cell mobilization. There were nine men and 13 women, with a median lupus nephritis duration of 46 (33-71) months. The mean number of CD34+ cells was (7.3±3.8)×106/kg. All patients had successful engraftment, and the median times of granulocyte and platelet engraftment were 8 (7-9) and 9 (6-10) days, respectively. The major complications of stem cell transplantation were fever and gastrointestinal tract symptoms. The treatment-related mortality was 5% (one of 22). After a median follow-up of 72 (60-80) months, 18 (82%) patients achieved completed remission, one (5%) patient achieved partial remission, and one patient had no response and received peritoneal dialysis at 12 months after transplantation. The 5-year overall survival and disease-free survival rates were 91% and 53%, respectively. Six patients experienced relapse during the follow-up, and the relapse rate was 27%. CONCLUSIONS: Autologous hematopoietic stem cell transplant could be used as a treatment option for refractory lupus nephritis, because it was relatively safe and associated with good outcomes.
Authors: Xiao Mei Leng; Ying Jiang; Dao Bing Zhou; Xin Ping Tian; Tai Sheng Li; Shu Jie Wang; Yong Qiang Zhao; Ti Shen; Xiao Feng Zeng; Feng Chun Zhang; Fu Lin Tang; Yi Dong; Yan Zhao Journal: Clin Exp Rheumatol Date: 2017-02-27 Impact factor: 4.473
Authors: Gabor G Illei; Ricard Cervera; Richard K Burt; Andrea Doria; Falk Hiepe; David Jayne; Steven Pavletic; Thierry Martin; Alberto Marmont; Riccardo Saccardi; Alexandre E Voskuyl; Dominique Farge Journal: Ann Rheum Dis Date: 2011-08-26 Impact factor: 19.103
Authors: Dominique Farge; Myriam Labopin; Alan Tyndall; Athanasios Fassas; Gian Luigi Mancardi; Jaap Van Laar; Jian Ouyang; Tomas Kozak; John Moore; Ina Kötter; Virginie Chesnel; Alberto Marmont; Alois Gratwohl; Riccardo Saccardi Journal: Haematologica Date: 2009-09-22 Impact factor: 9.941
Authors: J A Snowden; R Saccardi; M Allez; S Ardizzone; R Arnold; R Cervera; C Denton; C Hawkey; M Labopin; G Mancardi; R Martin; J J Moore; J Passweg; C Peters; M Rabusin; M Rovira; J M van Laar; D Farge Journal: Bone Marrow Transplant Date: 2011-10-17 Impact factor: 5.483